Molecular Pathway Modulation and Nanotechnology-Based Therapeutic Strategies for Shikonin

Area of Science:

• Oncology
• Pharmacology
• Nanomedicine

Background:

• Shikonin, derived from Radix lithospermi, exhibits diverse pharmacological activities, including anti-cancer effects.
• Shikonin targets Pyruvate kinase M2 (PKM2), a key enzyme in tumor metabolism, offering a potential strategy against malignancies.
• Current limitations in Shikonin's clinical application include targetability, cellular permeability, and in vivo safety issues.

Purpose of the Study:

• To review and synthesize recent advancements in Shikonin's anti-cancer efficacy.
• To explore Shikonin's mechanisms of action, clinical applications, and nano-based treatment optimizations.
• To provide a theoretical foundation for future research directions in Shikonin-based cancer therapy.

Main Methods:

• Systematic review of literature on Shikonin's anti-cancer properties and nano-based delivery systems.
• Analysis of Shikonin's role as a selective PKM2 inhibitory agent.
• Evaluation of Shikonin's effects on cancer cell growth, death, cell cycle, autophagy, and metastasis.

Main Results:

• Shikonin demonstrates significant inhibitory activity against various malignancies by modulating tumor metabolism and signaling pathways.
• Shikonin exerts anti-cancer effects by suppressing cell growth, inducing apoptosis, halting cell cycle, enhancing autophagy, and inhibiting metastasis.
• Nano-based strategies, including nanoparticles and nanocarriers, are essential for enhancing Shikonin's delivery, efficacy, and safety.

Conclusions:

• Shikonin holds promise as an anti-cancer agent, particularly when delivered via nano-based therapeutic strategies.
• Further preclinical research is required to optimize Shikonin nano-therapy, evaluate synergistic effects, and ensure safety.
• Clinical studies are needed to translate nano-based Shikonin therapy into effective cancer treatments.